Monday, July 17, 2017 7:53:36 PM
On the one hand, it is a shame that Roche flooded the market with a poor efficacy drug. It is also a shame that biosimilars of that subpar drug are going to be peddled by the likes of Amgen.
On the other hand, the fact that no other drug has supplanted Avastin in a head-to-head randomized Ph3 should remind us of the difficulty of this indication.
"... and hopefully VB-111 does too." EXACTLY! In several months, the whole world will learn that VB-111 is a transformative therapy for those with rGBM. I am still excited!
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM